HeartFlow, the leader in revolutionizing precision heart care, announced the close of a $215M Series F funding round by its parent company, HeartFlow Holding, Inc. led by Bain Capital Life Sciences with participation from new investor, Janus Henderson Investors, and existing investors, including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management.

This new funding will enable HeartFlow to meet the growing demand for its commercial products, support a robust body of growing clinical evidence and advance its comprehensive product portfolio to help physicians to diagnose coronary artery disease(CAD) and guide their treatment decisions.